KR20180036791A - 아프레밀라스트의 신규 형태 및 이를 제조하는 방법 - Google Patents

아프레밀라스트의 신규 형태 및 이를 제조하는 방법 Download PDF

Info

Publication number
KR20180036791A
KR20180036791A KR1020187008651A KR20187008651A KR20180036791A KR 20180036791 A KR20180036791 A KR 20180036791A KR 1020187008651 A KR1020187008651 A KR 1020187008651A KR 20187008651 A KR20187008651 A KR 20187008651A KR 20180036791 A KR20180036791 A KR 20180036791A
Authority
KR
South Korea
Prior art keywords
suspension
process according
temperature
amorphous
homogeneous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187008651A
Other languages
English (en)
Korean (ko)
Inventor
시아오-핑 팡
웨이-수오 로
관 순 왕
유-셍 린
층-쳉 후
유안창 후앙
Original Assignee
시노팜 타이완 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시노팜 타이완 리미티드 filed Critical 시노팜 타이완 리미티드
Publication of KR20180036791A publication Critical patent/KR20180036791A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y10S514/863—
    • Y10S514/925—

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020187008651A 2015-08-28 2016-08-25 아프레밀라스트의 신규 형태 및 이를 제조하는 방법 Ceased KR20180036791A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211280P 2015-08-28 2015-08-28
US62/211,280 2015-08-28
US201662279147P 2016-01-15 2016-01-15
US62/279,147 2016-01-15
PCT/SG2016/050413 WO2017039537A1 (en) 2015-08-28 2016-08-25 Novel forms of apremilast and the process of making the same

Publications (1)

Publication Number Publication Date
KR20180036791A true KR20180036791A (ko) 2018-04-09

Family

ID=58097541

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187008651A Ceased KR20180036791A (ko) 2015-08-28 2016-08-25 아프레밀라스트의 신규 형태 및 이를 제조하는 방법

Country Status (9)

Country Link
US (1) US9765026B2 (https=)
EP (1) EP3341360A4 (https=)
JP (1) JP2018528948A (https=)
KR (1) KR20180036791A (https=)
CN (1) CN107922332A (https=)
CA (1) CA2994217A1 (https=)
IL (1) IL257195A (https=)
TW (1) TWI613191B (https=)
WO (1) WO2017039537A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174685A1 (en) * 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
US10544097B2 (en) * 2015-08-27 2020-01-28 Msn Laboratories Private Limited Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
CN106977444B (zh) * 2016-01-18 2021-10-08 重庆医药工业研究院有限责任公司 一种阿普斯特无定型的制备方法
MY193175A (en) * 2016-03-30 2022-09-26 Sarudbhava Formulations Private Ltd Apremilast pharmaceutical compositions
CN107686461A (zh) * 2016-08-04 2018-02-13 广东东阳光药业有限公司 阿普斯特的溶剂化物及其制备方法和用途
WO2019021303A1 (en) * 2017-07-23 2019-01-31 Alkem Laboratories Limited NOVEL PROCESS FOR THE PREPARATION OF APREMILAST IN AMORPHOUS FORM
CN108440381A (zh) * 2018-03-15 2018-08-24 威海迪素制药有限公司 一种阿普斯特新晶型h及其制备方法
WO2022232037A1 (en) * 2021-04-26 2022-11-03 Amgen Inc. Process for synthesizing apremilast
JPWO2023120466A1 (https=) * 2021-12-23 2023-06-29

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
WO2007053503A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
CA2718601A1 (en) 2008-03-27 2009-10-01 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
BRPI1012770B8 (pt) * 2009-05-14 2021-05-25 Tianjin Hemay Bio Tech Co Ltd derivados de tiofeno
US8710043B2 (en) * 2011-06-24 2014-04-29 Amgen Inc. TRPM8 antagonists and their use in treatments
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
EP2730278A1 (en) 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
IN2014MU01283A (https=) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
CN104447445B (zh) 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
JP2018516912A (ja) 2015-05-26 2018-06-28 ルピン・リミテッド アプレミラストおよびその新規な多形の改善された製造方法
MX2017016054A (es) * 2015-06-09 2018-04-11 Dr Reddys Laboratories Ltd Proceso para la preparacion de apremilast y sus intermedios.

Also Published As

Publication number Publication date
JP2018528948A (ja) 2018-10-04
TW201718485A (zh) 2017-06-01
US20170057916A1 (en) 2017-03-02
EP3341360A4 (en) 2019-01-23
CA2994217A1 (en) 2017-03-09
CN107922332A (zh) 2018-04-17
WO2017039537A1 (en) 2017-03-09
TWI613191B (zh) 2018-02-01
IL257195A (en) 2018-03-29
EP3341360A1 (en) 2018-07-04
US9765026B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
KR20180036791A (ko) 아프레밀라스트의 신규 형태 및 이를 제조하는 방법
EP2970123B1 (en) Salt of omecamtiv mecarbil and process for preparing salt
CA3058209A1 (en) Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide
TWI453202B (zh) 製備拉帕替尼之方法及中間體
JP6985367B2 (ja) 新規化合物および方法
TW201321342A (zh) 用於製備喹啉衍生物之方法
JP6556293B2 (ja) 純粋なニロチニブ及びその塩の調製のための方法
AU2013274407A1 (en) Improved method of preparing oxymorphone
EP2350055A1 (en) Lenalidomide solvates and processes
CN117377667A (zh) 6-(环丙烷甲酰胺基)-4-((2-甲氧基-3-(1-甲基-1H-1,2,4-三唑-3-基)苯基)氨基)-N-(甲基-d3)哒嗪-3-甲酰胺的晶型
JP5524221B2 (ja) 合成中間体としてのチアゾリル−ピラゾロピリミジン化合物および関連合成方法
EP3027626A1 (en) A process for preparing rifaximin k
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
EP3105231A1 (en) A process for preparation of (2s,5r)-6-sulphooxy-7-oxo-2-[((3r)-piperidine-3-carbonyl)-hydrazinocarbonyl]-1,6-diaza-bicyclo[3.2.1] octane
WO2025068505A1 (en) Preparation of bridged pentacyclic imidazole derivatives as modulators of tnf activity, intermeditates and their preparation
JP7617043B2 (ja) ｔｅｒｔ－ブチル（Ｓ）－２－（（２Ｓ，３Ｒ）－１－アミノ－３－ヒドロキシ－１－オキソブタン－２－イル）－１－オキソ－２，５－ジアザスピロ［３．４］オクタン－５－カルボキシレートの固体形態およびそれらを調製する方法
KR101469015B1 (ko) 몬테루카스트의 제조방법 및 이에 사용되는 중간체
CN116419922A (zh) 一种从泊马度胺选择性合成3,6′-二硫代泊马度胺的方法
CN115181093B (zh) Sunvozertinib中间体的制备方法
CN115925713B (zh) 二氮杂大环类化合物中间体及其制备方法和应用
CN110872272A (zh) 一种环己烷衍生物的盐
CN110872270A (zh) 一种环己烷衍生物的盐
JP2026509733A (ja) ピペリジノ―ジヒドロチエノピリミジンスルホキシドの新規多形
JP2020536100A (ja) シス−４−［２−｛［（３ｓ，４ｒ）−３−フルオロキサン−４−イル］アミノ｝−８−（２，４，６−トリクロロアニリノ）−９ｈ−プリン−９−イル］−１−メチルシクロヘキサン−１−カルボキサミドの製造プロセス
CN115368319A (zh) 一种苄肼类化合物的制备方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180716

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200113

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200324

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200113

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I